IAVI 002

Status:Completed

Phase:I

Principal Investigator(s):

Objective:Evaluate the safety and immunogenicity of a candidate HIV-1 clade A DNA vaccine.

Prevention Option(s):HIV Vaccine

Study Design:Controlled, Double-blind, Placebo, Randomized

Arms and Assigned Interventions

DescriptionOn Days 0 and 21 participants will receive a single injection of 500mg pTHr.HIVA in 1.0mL saline

Mode of DeliveryIntramuscular

ARMsExperimental

Official Code: IAVI 002

Trial Sponsors: Kenya AIDS Vaccine Initiative-Kenyatta National Hospital (KAVI-KNH)

Start Date

End Date

none

Enrollment:18

Age range: ↔ any

Population:Cisgender Men, Cisgender Women